PROCEDURE FOR THE PROOF AND/OR FOR THE MEASUREMENT MORE LIPASEODER PHOSPHOLIPASEAKTIVITÄT WITH HIGH SPEED

Biomarker for the diagnosis of pulmonary hypertension (PH)

The present invention relates to a method of diagnosing pulmonary hypertension (PH) in a patient, a method of monitoring the course of pulmonary hypertension in a patient, a method of determining the severity of pulmonary hypertension in a patient, and a method of differentiating between pulmonary hypertension and at least one condition selected from a group consisting of a disease associated with a risk of developing pulmonary hypertension and metabolic syndrome. In addition, the present invention relates to a kit comprising means for carrying out the above methods.

System and method for diagnosing and managing those at risk for cardiovascular disease

METHOD FOR DETERMINATION OF TRIGLYCERIDES AND GLYCEROL

SYSTEM AND METHOD FOR DIAGNOSING AND MANAGING THOSE AT RISK FOR CARDIOVASCULAR DISEASE

A system and method for diagnosing and managing patients at risk for cardiovascular disease. The system and method provides for automating the ordering of a number of advanced tests, compiling and evaluating test results, and produci ng an automated report which includes recommended disease management options. ...

Biomarkers

NON-HIGH DENSITY LIPOPROTEIN DERIVED CVD MARKERS

The present invention inter alia relates to methods and uses involving the determination of lipid/lipid concentration ratios in order to diagnose, predict, prevent and/or treat atherosclerosis or cardiovascular disease (CVD) and its complications including, e.g., acute myocardial infarction. The methods include analyzing lipid concentrations and resulting lipid/lipid concentration ratios of a non-high density lipoprotein samples from patients and comparing them to a control.

Nanoveson(TM): Treatment, Biomarkers and Diagnostic Tests for Liver Diseases and Comormid Disease

A method of treatment of liver diseases and comorbid diseases is disclosed wherein an oral dose of lipids in an amount effective to trigger the release of cholecystokinin (CCK) into the duodenum to generate a major release of bile phospholipids from remodeled stores of triglycerides (TAG) in the liver, is administered to a patient in need thereof, thereby causing the formation of sequestered and aggregated mixed micelles and vesicles (SAMMVs) in the intestines of the patient which are then eliminated via the bowels of the patient. 111.-. (canceled)11. A kit for treating liver disease involving an excess of triglycerides in the liver of a patient , comprising (i) at least one dose of a cathartic in an amount effective to evacuate the intestines of the patient; and (ii) an oral dose of about 100±30 grams lipids comprising a solution of lipids and fatty acids.1224.-. (canceled)25. A method of diagnosing a disease or a medical disorder which comprises (i) administering to a human patient in need thereof an oral dose of about 100±30 grams lipids in an amount effective to trigger the release of cholecystokinin (CCK) into the duodenum to generate a release of bile phospholipids from remodeled stores of triglycerides in the liver of the patient , in an amount effective to cause the formation of sequestered and aggregated mixed micelles and vesicles (SAMMVs) and aqueous solution (AQ) in the intestines of the patient which are then eliminated via the bowels of the patient; and (ii) analyzing contents of the SAMMVs and/or the AQ produced for biomarkers to diagnose the disease or the medical disorder.26. The method of claim 25 , wherein the content of the SAMMVs produced by the administration claim 25 , provides the biomarkers to diagnose the disease or the medical disorder.27. The method of claim 25 , wherein the content of the aqueous solution (AQ) produced claim 25 , either when the SAMMVs are produced or when the SAMMVs are no longer produced by the administration of the ...

Methods for measuring and monitoring a meat characteristic of a livestock animal from a sample obtained from a non-meat location of the livestock

The invention is directed to a method of livestock breeding, meat production and marketing, histology, and genetics using a biopsy sample from a non-meat location of the livestock to provide information about the meat quality of the livestock.

MEANS AND METHODS FOR ASSESSING NEURONAL TOXICITY

The present invention relates to the field of diagnostics for neuronal toxicity and toxicological assessments for risk stratification of chemical compounds. Specifically, it relates to a method for diagnosing neuronal toxicity. It also relates to a method for determining whether a compound is capable of inducing such neuronal toxicity in a subject and to a method of identifying a drug for treating neuronal toxicity. Furthermore, the present invention relates to a device and a kit for diagnosing neuronal toxicity.

MEANS AND METHODS FOR ASSESSING NEURONAL TOXICITY

The present invention relates to the field of diagnostics for neuronal toxicity and toxicological assessments for risk stratification of chemical compounds. Specifically, it relates to a method for diagnosing neuronal toxicity. It also relates to a method for determining whether a compound is capable of inducing such neuronal toxicity in a subject and to a method of identifying a drug for treating neuronal toxicity. Furthermore, the present invention relates to a device and a kit for diagnosing neuronal toxicity.

METHOD FOR DETERMINATION OF TRIGLYCERIDES AND GLYCEROL

SYSTEM AND METHOD FOR DIAGNOSING AND MANAGING PATIENTS HAVING RISK OF CARDIOVASCULAR DISEASE

PROBLEM TO BE SOLVED: To provide a method for supporting the evaluation and management of the risk of lipids and metabolism concerning cardiovascular diseases. SOLUTION: The method includes the steps of: determining a fasting triglyceride (TG) level of an individual from a first sample derived from the individual; when the TG level of the individual is greater than 70 mg/dl and less than 200 mg/dl, testing, for small-particle low-density lipoprotein (LDL), a second sample derived from the individual; and determining a low-density lipoprotein-cholesterol (LDL-C) level of the individual from a third sample derived from the individual. COPYRIGHT: (C)2009,JPO&INPIT ...

METHOD FOR DETERMINATION OF TRIGLYCERIDES AND GLYCEROL

DIAGNOSTIC METHODS BASED ON LIPID PROFILES

The present invention relates to methods for the diagnosis of NAFLD in a subject, and for the differential diagnosis of NASH or steatosis in a subject suffering from NAFLD, based on the determination in a sample of metabolic markers, particularly lipid metabolic markers.

CHOLESTEROL EFFLUX CAPACITY ASSESSMENT

A method is provided for transforming one or more biomarkers into a cholesterol efflux capacity (CEC) value. Methods relate to determining SR-BI-mediated and ABCA1 -mediated CEC. CEC may be used for compound screening and to determine risk of cardiovascular disease and to recommend or administer treatment regimens.

METHOD FOR DETERMINATION OF TRIGLYCERIDES AND GLYCEROL

LIPID BIOMARKERS OF HEALTHY AGEING

In one aspect there is provided a method for predicting a risk of unhealthy ageing in a subject, comprising: (a) determining a level of two or more lipid biomarkers in a sample from the subject, wherein the biomarkers are selected from two or more of the following groups:(i) a triacylglycerol (TAG) from TAG (46:5) to TAG (54:3);(ii) an ether phosphatidylcholine (PC- O) from PC-O(28:0) to PC-O(38:6); (iii) a sphingomyelin (SM) from SM (33:1) to SM(50:1); (iv) a phosphatidylcholine (PC) from PC (32:1) to PC (40:5); (v) a phosphatidylinositol (PI) from PI (36:1) to PI (38:3); (vi) a phosphatidylethanolamine (PE) from PE (36:2) to PE (38:4); and (b) comparing the levels of the biomarkers in the sample to reference values;wherein the levels of the biomarkers in the sample compared to the reference values are indicative of the risk of unhealthy ageing in the subject.

BIOMARKER FOR THE DIAGNOSIS OF PULMONARY HYPERTENSION (PH)

The present invention relates to a method of diagnosing pulmonary hypertension (PH) in a patient, a method of monitoring the course of pulmonary hypertension in a patient, a method of determining the severity of pulmonary hypertension in a patient, and a method of differentiating between pulmonary hypertension and at least one condition selected from a group consisting of a disease associated with a risk of developing pulmonary hypertension and metabolic syndrome. In addition, the present invention relates to a kit comprising means for carrying out the above methods.

DIABETES PANEL

The present invention generally relates to predicting the risk of developing diabetes in patients who currently do not have diabetes. The invention can involve obtaining a sample from a patient negative for diabetes, conducting an assay on the sample to obtain a level of a glycated albumin, and determining an elevated risk of developing a diabetic condition if said level exceeds a predetermined threshold. Other parameters that may be assessed is the level of glucose, adiponectin, and/or triglycerides.

PROCEEDED OF DETECTION AND/OR MEASUREMENT High banc Of an ACTIVITY LIPASIQUE HAS

MULTI-METABOLITES PLATFORM FOR DIAGNOSIS OF ACUTE CORONARY SYNDROME

The present disclosure provides a multi-metabolite platform using one or more metabolite selected from a group consisting of tryptophan, homoserine, fatty acid (16:1), fatty acid (18:0), fatty acid (18:1), fatty acid (18:2), fatty acid (22:6), phosphatidylcholine (PC) (34:2), PC (34:3), lysophosphatidylcholine (lysoPC) (16:0), lysoPC (18:0), lysoPC (20:3), lysoPC (20:4), lysoPC (22:6), monoglyceride (18:1/0:0/0:0) and sphingomyelin (d18:2/16:0) as a biomarker, which can diagnose acute coronary syndrome as well as the symptoms occurring prior to the onset of the disease simply and accurately through in-vivo level analysis. 1. A kit for diagnosis of acute coronary syndrome , comprising an in-vivo level detector of one or more metabolite selected from a group consisting of tryptophan , homoserine , phosphatidylcholine (PC) (34:2) , PC (34:3) , lysophosphatidylcholine (lysoPC) (16:0) , lysoPC (20:4) , lysoPC (22:6) , monoglyceride (18:1/0:0/0:0) and sphingomyelin (d18:2/16:0).2. The kit for diagnosis of acute coronary syndrome according to claim 1 , which further comprises an in-vivo level detector of one or more metabolite selected from a group consisting of fatty acid (16:1) claim 1 , fatty acid (18:0) claim 1 , fatty acid (18:1) claim 1 , fatty acid (18:2) claim 1 , fatty acid (22:6) claim 1 , lysoPC (18:0) and lysoPC (20:3).3. The kit for diagnosis of acute coronary syndrome according to claim 1 , wherein the in-vivo level detector of the metabolite comprises a composition for diagnosis of acute coronary syndrome comprising a material for detecting one or more metabolite selected from a group consisting of tryptophan claim 1 , homoserine claim 1 , phosphatidylcholine (PC) (34:2) claim 1 , PC (34:3) claim 1 , lysophosphatidylcholine (lysoPC) (16:0) claim 1 , lysoPC (20:4) claim 1 , lysoPC (22:6) claim 1 , monoglyceride (18:1/0:0/0:0) and sphingomyelin (d18:2/16:0) as an active ingredient.4. The kit for diagnosis of acute coronary syndrome according to claim 2 , ...

METHOD FOR THE HIGH-SPEED DETECTION AND/OR MEASUREMENT OF A LIPASE OR PHOSPHOLIPASE ACTIVITY

L'invention concerne un procédé de détection et/ou de mesure in vitro d'une activité lipasique ou phospholipasique, caractérisé en ce qu'il comprend : l'addition d'un échantillon susceptible de contenir une lipase ou phospholipase dans les puits de plaques de microtitration revêtus d'une couche d'un substrat lipidique pouvant être hydrolyse par ladite lipase ou phospholipase en libérant de l'acide α-éléostéarique ; la détection et/ou la mesure de l'activité lipasique ou phospholipasique par spectrophotométrie UV de l'acide α-éléostéarique libéré lors de l'étape précédente. L'invention concerne également l'application du procédé susmentionné au diagnostic in vitro de pathologies liées à une augmentation du taux plasmatique de lipase.

Microtitration plates comprising wells coated with a lipid substrate and a method of preparing

A method for the detection and/or measurement in vitro of a lipase or phospholipase activity, including the addition of a sample likely to contain said lipase or phospholipase into the wells of microtitration plates coated with a layer of a lipid substrate which is able to be hydrolyzed by the lipase or phospholipase by releasing α-eleostearic acid, and the detection and/or the measurement of the lipase or phospholipase activity by UV spectrophotometry of the α-eleostearic acid released during the previous stage. The application of this method to the in vitro diagnosis of pathologies linked to an increase in the plasma lipase level.

METHOD FOR DETERMINING LIVER FAT AMOUNT AND METHOD FOR DIAGNOSING NAFLD

MARKERS OF NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) AND NON-ALCOHOLIC STEATOHEPATITIS (NASH) AND METHODS OF USE THEREOF

Novel methods for assessing the level of triglycerides in the liver of a subject are described, comprising determining the amount of a lipid metaboli te in a sample from a body fluid of the subject. The methods may be used, fo r example, in diagnosing and monitoring liver disorders such as steatosis, N AFLD and NASH.

PROCEEDED OF DETECTION AND/OR MEASUREMENT High banc Of an ACTIVITY LIPASIQUE HAS

L'invention concerne un procédé de détection et/ou de mesure in vitro d'une activité lipasique, caractérisé en ce qu'il comprend : - l'addition d'un échantillon susceptible de contenir une lipase dans les puits de plaques de microtitration revêtus d'une couche d'un substrat lipidique pouvant être hydrolysé par ladite lipase en libérant de l'acide α-éléostéarique, - la détection et/ou la mesure de l'activité lipasique par spectrophotométrie UV de l'acide α-éléostéarique libéré lors de l'étape précédente. L'invention concerne également l'application du procédé susmentionné au diagnostic in vitro de pathologies liées à une augmentation du taux plasmatique de lipase.

A METHOD OF DIAGNOSING CANCER BASED ON LIPIDOMIC ANALYSIS OF A BODY FLUID

Nanoveson(TM): Treatment, Biomarkers and Diagnostic Tests for Liver Diseases and Comorbid Disease

A method of treatment of liver diseases and comorbid diseases is disclosed wherein an oral dose of lipids in an amount effective to trigger the release of cholecystokinin (CCK) into the duodenum to generate a major release of bile phospholipids from remodeled stores of triglycerides (TAG) in the liver, is administered to a patient in need thereof, thereby causing the formation of sequestered and aggregated mixed micelles and vesicles (SAMMVs) in the intestines of the patient which are then eliminated via the bowels of the patient. 111.-. (canceled)12. A kit for treating liver disease involving an excess of triglycerides in the liver of a patient , comprising (i) at least one dose of a cathartic in an amount effective to evacuate the intestines of the patient; and (ii) an oral dose of about 100±30 grams lipids comprising a solution of lipids and fatty acids.1324.-. (canceled)25. A method of diagnosing a disease or a medical disorder which comprises (i) administering to a human patient in need thereof an oral dose of about 100±30 grams lipids in an amount effective to trigger the release of cholecystokinin (CCK) into the duodenum to generate a release of bile phospholipids from remodeled stores of triglycerides in the liver of the patient , in an amount effective to cause the formation of sequestered and aggregated mixed micelles and vesicles (SAMMVs) and aqueous solution (AQ) in the intestines of the patient which are then eliminated via the bowels of the patient; and (ii) analyzing the SAMMVs and/or the AQ produced for biomarkers to diagnose the disease or the medical disorder.26. The method of claim 25 , wherein the SAMMVs produced by the administration claim 25 , provides the biomarkers to diagnose the disease or the medical disorder.27. The method of claim 25 , wherein the aqueous solution (AQ) produced claim 25 , either when the SAMMVs are produced or when the SAMMVs are no longer produced by the administration of the oral dose claim 25 , provides the biomarkers ...

MEANS AND METHODS FOR DIAGNOSING HEART FAILURE IN A SUBJECT

The present invention relates to the field of diagnostic methods. Specifically, the present invention contemplates a method for diagnosing heart failure in a subject based on determining the amounts of at least three biomarkers. The invention also relates to tools for carrying out the aforementioned methods, such as diagnostic devices.

LIPID BIOMARKERS FOR THE DIAGNOSIS OF CANCER

BIOMARKER FOR THE DIAGNOSIS OF PULMONARY HYPERTENSION (PH)

The present invention relates to a method of diagnosing pulmonary hypertension (PH) in a patient, a method of monitoring the course of pulmonary hypertension in a patient, a method of determining the severity of pulmonary hypertension in a patient, and a method of differentiating between pulmonary hypertension and at least one condition selected from a group consisting of a disease associated with a risk of developing pulmonary hypertension and metabolic syndrome. In addition, the present invention relates to a kit comprising means for carrying out the above methods. 1. A method of diagnosing pulmonary hypertension (PH) in a patient comprising the step of:determining the level of one or more free fatty acids (FFA) in a biological sample from a patient.3. The method of claim 1 , wherein the step of determining the level of one or more free fatty acids in a biological sample from a patient comprisesdetermining the level of one or more first free fatty acids and the level of one or more second free fatty acids, and wherein preferably the method further comprises the step of:determining the ratio of the level of one or more first free fatty acids and the level of one or more second free fatty acids.4. A method of monitoring the course of pulmonary hypertension in a patient comprising the step of:determining the level of one or more free fatty acids in a biological sample from a patient.5. The method of claim 4 , wherein the method further comprises the step of:determining the level of one or more compounds selected from the group consisting of triacylglyceroles (TAGs), diacylglyceroles (DAGs), membrane lipids, and lysolipids, and wherein preferably the method further comprises the step of:determining the ratio of the level of one or more free fatty acids and the level of one or more compounds selected from the group consisting of triacylglyceroles (TAGs), diacylglyceroles (DAGs), membrane lipids, and lysolipids.7. A method of determining the severity of pulmonary ...

Markers of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) and methods of use thereof

Lipid biomarkers of healthy ageing

In one aspect there is provided a method for predicting a risk of unhealthy ageing in a subject, comprising: (a) determining a level of two or more lipid biomarkers in a sample from the subject, wherein the biomarkers are selected from two or more of the following groups:(i) a triacylglycerol (TAG) from TAG (46:5) to TAG (54:3);(ii) an ether phosphatidylcholine (PC- O) from PC-O(28:0) to PC-O(38:6); (iii) a sphingomyelin (SM) from SM (33:1) to SM(50:1); (iv) a phosphatidylcholine (PC) from PC (32:1) to PC (40:5); (v) a phosphatidylinositol (PI) from PI (36:1) to PI (38:3); (vi) a phosphatidylethanolamine (PE) from PE (36:2) to PE (38:4); and (b) comparing the levels of the biomarkers in the sample to reference values;wherein the levels of the biomarkers in the sample compared to the reference values are indicative of the risk of unhealthy ageing in the subject.

Methods and products for labelling lipids

The present disclosure relates to methods and products for labelling, binding and/or detection of lipids. Certain embodiments provide a method of labelling a lipid. The method comprises exposing the lipid to a complex comprising a transition metal carbonyl compound, a conjugated bidentate ligand and a tetrazolato compound, and thereby labelling the lipid by binding the complex to the lipid.

Diabetes panel

The present invention generally relates to predicting the risk of developing diabetes in patients who currently do not have diabetes. The invention can involve obtaining a sample from a patient negative for diabetes, conducting an assay on the sample to obtain a level of a glycated albumin, and determining an elevated risk of developing a diabetic condition if said level exceeds a predetermined threshold. Other parameters that may be assessed is the level of glucose, adiponectin, and/or triglycerides.

STRIP FOR MEASURING BLOOD LIPIDS

The present invention relates to a strip for measuring blood lipids. The strip for measuring blood lipids, of the present invention, presses, with an optimal pressure or to an optimal height, a contact surface of a protruding part of a measurement layer disposed between an upper cover and a lower substrate, so as to improve the uniform diffusion of a biological sample, thereby having an effect of increasing measurement result accuracy of the biological sample. 1. A strip for measuring blood lipids comprising:an upper cover coupled to a lower substrate and comprising an upper opening window configured to expose a measurement region of a measurement layer and a protruding part formed to protrude in a coupling direction to the lower substrate along edges of the upper opening window;a lower substrate coupled to the upper cover and comprising a recessed part into which the protruding part is inserted by surrounding an external circumference of the protruding part of the upper cover; anda measurement layer configured to determine a reaction with a biological sample, and disposed on the recessed part of the lower substrate and pressed by the protruding part of the upper cover when the lower substrate is coupled to the upper cover;wherein a spacing interval between a bottom part of the protruding part and the bottom of the recessed part when the lower substrate is coupled to the upper cover in a state in which the measurement layer is not inserted is in a range of 0.5 to 0.8 mm.2. The strip for measuring blood lipids according to claim 1 , wherein a contact surface of the measurement layer with the protruding part is pressed between the protruding part and the recessed part so that the biological sample is uniformly spread in all directions with respect to the measurement layer.3. The strip for measuring blood lipids according to claim 1 , wherein the measurement layer comprises a diffusion layer configured to diffuse a biological sample to be introduced claim 1 , a ...

MEANS AND METHODS FOR DIAGNOSING CARDIAC DISEASE IN A SUBJECT

The present invention relates to the field of diagnostic methods. Specifically, the present invention contemplates a method for diagnosing a cardiac disease in a subject based on determining the amounts of at least three lipid metabolite biomarkers and at least one further cardiac biomarker. The invention also relates to tools for carrying out the aforementioned methods, such as diagnostic devices. 1. A method for diagnosing cardiac disease comprising the steps of:a. determining in a sample of a subject the amounts of at least three lipid metabolite biomarkers and of at least one additional cardiac biomarker, andb. comparing the amounts as determined in step a. to a reference, whereby cardiac disease is to be diagnosed.2. The method of claim 1 , wherein said at least three lipid metabolite biomarkers are:i. at least one triacylglyceride biomarker, at least one cholesterylester biomarker, and at least one phosphatidylcholine biomarker;ii. at least one triacylglyceride biomarker, at least one phosphatidylcholine biomarker, and at least one sphingomyelin biomarker;iii. at least one triacylglyceride biomarker, at least one cholesterylester biomarker, and at least one sphingomyelin biomarker;iv. at least one phosphatidylcholine biomarker, at least one cholesterylester biomarker, and at least one sphingomyelin biomarker;v. Cholesterylester C18:2, SSS and Cer(d17:1/24:0);vi. at least two sphingomyelin biomarkers selected from the group consisting of SM2, SM3, SM5, SM18, SM23, SM24, and SM28, and at least one triacylglyceride biomarker selected from the group consisting of SOP2, SPP1 and PPO1, (or alternatively at least one triacylglyceride biomarker selected from the group consisting of SOP2, SPP1 and PPP);vii. at least two triacylglyceride biomarkers selected from the group consisting of OSS2, SOP2, SPP1 and SSP2, and at least one sphingomyelin biomarker selected from the group consisting of SM23 and SM24;viii. SM18, SM24 and SM28; orix. the biomarkers of panel 1, 2, 3, 4 ...

TREATMENT OF AUTOPHAGY-RELATED DISORDERS

The present invention relates to the use of neutral lipids, including triglycerides, diglycerides and monoglycerides which may be used to increase neutral lipids (lipid stores and/or lipid droplets) and neutral lipid stores in order to regulate (in particular, induce) autophagy and treat and/or prevent autophagy related disease states and/or conditions. In one embodiment, the invention relates to the use of neutral lipids and/or TRIM proteins which may be used to regulate (in particular, induce) autophagy, target autophagic substrates and treat and/or prevent autophagic disease states and/or conditions.

Biomarker for the diagnosis of pulmonary hypertension (PH)

The present invention relates to a method of diagnosing pulmonary hypertension (PH) in a patient, a method of monitoring the course of pulmonary hypertension in a patient, a method of determining the severity of pulmonary hypertension in a patient, and a method of differentiating between pulmonary hypertension and at least one condition selected from a group consisting of a disease associated with a risk of developing pulmonary hypertension and metabolic syndrome. In addition, the present invention relates to a kit comprising means for carrying out the above methods.

METHOD OF DIAGNOSING IRRITABLE BOWEL SYNDROME IBS

Novel biomarkers associated with irritable bowel syndrome (IBS) have been found. The invention provides methods of diagnosing IBS by determining said biomarkers in samples taken from subjects suffering from the disease. Appropriate biomarkers includes certain lipids and/or certain non-lipid metabolites. Particularly suitable biomarkers are lipids involved in the metabolism of acylglycerol and sphingolipids, such as acylglycerols e.g. triacylglycerols (TG), and diacylglycerols (DG), glycerophospholipids, especially lysophospholipids such as lysophos- phatidylcholines (LysoPC) and lysophosphatidylethanolamines (LysoPE), and sphingolipids, especially ceramides (Cer) and glycosphingolipids (GlycoSL). A great number of lipids and/or water-soluble other metabolites may be determined simultaneously to obtain a metabolite profile of the subject.

BIOMARKERS

... in one aspect., the present Invention provides a method of determining cardiovascular disease (CVD) risk in a subject comprising (a) determining fatty acid composition of lipids In a sample obtained from the subject, wherein the lipids are selected from the group consisting of: (I) triacylgiycerols (TAGs); and cholesterol esters (CEs); and (b) comparing the fatty acid composition of the lipids in the sample from the subject to a control; wherein a decrease in mean fatty acid chain length in the lipids in the sample from the subject compared to the control indicates an. increased risk of CVD in the subject; and wherein the. CVD is associated with atherosclerotic plaque rupture or thrombosis., and/or the CVD Is an acute ischemic event selected from myocardial infarction, ischemic stroke or sudden cardiac death.

COMPOSITIONS AND METHODS FOR REDUCING A FATTY ACID DESATURATION INDEX IN A SUBJECT IN NEED THEREOF

In various embodiments, the present invention provides compositions and methods for treating and/or preventing cardiovascular-related diseases in subject in need thereof.

Method of quantifying cholesterol in triglyceride-rich lipoprotein, and reagent therefor

A method of specifically quantifying cholesterol in triglyceride-rich lipoprotein (TRL-C) in a test sample without requiring complicated operations, and a reagent therefor are disclosed. The method of quantifying cholesterol in triglyceride-rich lipoprotein comprises a step (1) of selectively erasing cholesterol in lipoproteins other than the cholesterol in triglyceride-rich lipoprotein by treating the test sample with a cholesterol esterase having a molecular weight of more than 50 kDa and a surfactant; and quantifying the remaining cholesterol in TRL (TRL-C).

Lipid biomarkers of healthy ageing

MEANS AND METHODS FOR ASSESSING NEURONAL TOXICITY

The present invention relates to the field of diagnostics for neuronal toxicity and toxicological assessments for risk stratification of chemical compounds. Specifically, it relates to a method for diagnosing neuronal toxicity. It also relates to a method for determining whether a compound is capable of inducing such neuronal toxicity in a subject and to a method of identifying a drug for treating neuronal toxicity. Furthermore, the present invention relates to a device and a kit for diagnosing neuronal toxicity.

Biomarkers of Breast and Lung Cancer

Provided herein are methods of detecting lipids in humans suspected of having cancer, in particular detecting lipids in samples from a human suspected of having breast or lung cancer.

Determination of interferents in a sample

폐고혈압 (PH)의 진단을 위한 바이오마커

... 본 발명은 환자에서 폐고혈압 (pulmonary hypertension)을 진단하는 방법, 환자에서 폐고혈압의 진행을 모니터링하는 방법, 환자에서 폐고혈압의 경중도를 결정하는 방법, 및 폐고혈압 발병 위험과 연관된 질병 및 대사 증후군으로 이루어지는 군에서 선택되는 적어도 하나의 상태와 폐고혈압을 구별하는 방법에 관한 것이다. 나아가, 본 발명은 상기 방법을 수행하기 위한 수단을 포함하는 키트에 관한 것이다.

Strip for measuring blood lipids

The present invention relates to a strip for measuring blood lipids. The strip for measuring blood lipids, of the present invention, presses, with an optimal pressure or to an optimal height, a contact surface of a protruding part of a measurement layer disposed between an upper cover and a lower substrate, so as to improve the uniform diffusion of a biological sample, thereby having an effect of increasing measurement result accuracy of the biological sample.

MARCADORES DE DOENÇA HEPÁTICA GORDUROSA NÃO ALCOÓLICA (NAFLD) E ESTEATOHEPATITE NÃO ALCOÓLICA (NASH) E MÉTODOS DE USO DOS MESMOS

A METHOD OF DIAGNOSING CANCER BASED ON LIPIDOMIC ANALYSIS OF A BODY FLUID

A method of diagnosing cancer based on lipidomic analysis of a body fluid taken from the body of a patient is disclosed. The method includes the steps of spiking of the sample with a set of internal standards having at least one internal standard for each lipid class present in the sample, subsequently processing the sample by liquid-liquid lipidomic extraction or by solid phase lipidomic extraction, measurement of the processed sample by a mass spectrometry method, determining concentrations for at least 51, more preferably for all lipids present at a level above detection threshold of the mass spectrometry method, statistical evaluation of the determined concentrations of the lipids, the statistical evaluation determining the level of probability of the patient suffering from cancer, or optionally from a specific type of cancer. 1. A method of diagnosing cancer based on lipidomic analysis of a body fluid taken from the body of a patient , characterized in that said method comprises the steps of:spiking of the sample with a set of internal standards comprising at least one internal standard for each lipid class present in the sample,subsequently processing the sample by liquid-liquid lipidomic extraction or by solid phase lipidomic extraction,measurement of the processed sample by a mass spectrometry method,determining concentrations for at least 51 lipids, more preferably for all lipids present at a level above detection threshold of the mass spectrometry method, using the internal standards for the corresponding lipid classes for the quantitation, or using relative concentrations, or using ratios of concentrations and/or signal intensities,statistical evaluation of the determined concentrations of the lipids, said statistical evaluation determining the level of probability of the patient suffering from cancer, or optionally from a specific type of cancer, based on the determined lipid concentrations compared to a cancerous pattern, or optionally a specific ...

METHOD FOR THE HIGH-SPEED DETECTION AND/OR MEASUREMENT OF A LIPASE OR PHOSPHOLIPASE ACTIVITY

REACTING COMPOSITION AND PROCESS FOR THE DETERMINATION OF CONCENTRATIONS OF GLICEROL IN BIOLOGICAL FLUIDS

METHOD FOR DETERMINING LIVER FAT AMOUNT AND METHOD FOR DIAGNOSING NAFLD

The present invention is based on the idea of determining certain molecular lipids from a subject's blood sample, for example from serum or plasma sample, and based on the amounts of the determined lipids determining the amount of liver fat and/or diagnosing NAFLD in the subject. More specifically the subjects with elevated liver fat amount and NAFLD are characterized by elevated triglycerides with low carbon number and double bond content in the blood sample. Lysophosphatidylcholines, ether phospholipids, sphingomyelins and PUFA-containing phospholipids are diminished in the blood samples of subjects with an elevated liver fat amount and NAFLD. The method of the present invention can be further used for monitoring the subject's response to the treatment of NAFLD or to the treatment of lowering of the liver fat amount in the subject.

LIPID BIOMARKERS FOR THE DIAGNOSIS OF CANCER

The present disclosure provides a cancer biomarker for a patient suffering from pleural effusion, a method of determining whether a patient suffering from pleural effusion has cancer, and a method of treating cancer in a patient suffering from pleural effusion. Disclosed herein also include a cancer biomarker for the detection of cancer with EGFR mutation, a method of determining whether a patient suffering from cancer has EGFR mutation, and a method of treating cancer in a patient with EGFR mutation. 1. A cancer biomarker for a patient suffering from pleural effusion , wherein the biomarker is at least two selected from the group consisting of: fatty acid (22:6) , hydroxyl fatty acid (16:0) , fatty acid (20:1) , fatty acid (18:2) , fatty acid (18:1) , fatty acid (16:1) , fatty acid (20:5) , fatty acid (22:4) , fatty acid (22:5) , fatty acid (20:4) and fatty acid (20:2) , and wherein the cancer is selected from lung cancer , breast cancer , gastric cancer and squamous cell carcinoma.2. The cancer biomarker of claim 1 , wherein the biomarker is selected from the group consisting of: (1) fatty acid (22:6) and hydroxyl fatty acid (16:0); (2) fatty acid (22:6) claim 1 , hydroxyl fatty acid (16:0) and fatty acid (18:2); (3) fatty acid (22:6) claim 1 , hydroxyl fatty acid (16:0) claim 1 , fatty acid (18:2) and fatty acid (18:1); (4) fatty acid (22:6) claim 1 , hydroxyl fatty acid (16:0) claim 1 , fatty acid (18:2) claim 1 , fatty acid (18:1) and fatty acid (22:5); (5) fatty acid (22:6) claim 1 , hydroxyl fatty acid (16:0) claim 1 , fatty acid (18:2) claim 1 , fatty acid (18:1) claim 1 , fatty acid (22:5) and fatty acid (20:4); (6) fatty acid (22:6) claim 1 , hydroxyl fatty acid (16:0) claim 1 , fatty acid (18:2) claim 1 , fatty acid (18:1) claim 1 , fatty acid (22:5) claim 1 , fatty acid (20:4) and fatty acid (20:2); (7) fatty acid (22:6) claim 1 , hydroxyl fatty acid (16:0) claim 1 , fatty acid (18:2) claim 1 , fatty acid (18:1) claim 1 , fatty acid (22:5) claim 1 , ...

Multi-metabolites platform for diagnosis of acute coronary syndrome

The present disclosure provides a multi-metabolite platform using one or more metabolite selected from a group consisting of tryptophan, homoserine, fatty acid (16:1), fatty acid (18:0), fatty acid (18:1), fatty acid (18:2), fatty acid (22:6), phosphatidylcholine (PC) (34:2), PC (34:3), lysophosphatidylcholine (lysoPC) (16:0), lysoPC (18:0), lysoPC (20:3), lysoPC (20:4), lysoPC (22:6), monoglyceride (18:1/0:0/0:0) and sphingomyelin (d18:2/16:0) as a biomarker, which can diagnose acute coronary syndrome as well as the symptoms occurring prior to the onset of the disease simply and accurately through in-vivo level analysis.

급성 관상동맥 증후군 질환 진단용 다중 생체 대사체 플랫폼

The present invention relates to a pharmaceutical composition comprising tryptophan, homoserine, fatty acid 16: 1, fatty acid 18: 0, fatty acid 18: 1, fatty acid 18: 2, fatty acid 22: 6), phosphatidylcholine (PC) 34: 2, PC 34: 3, lysophosphatidylcholine 16: 0, lycor PC 18: 0, (18: 1/0: 0/0: 0) and sphingomyelin (d18: 4), lycoricone PC (20: 2 < / RTI >: 16: 0) as a biomarker, the present invention provides a multi-body metabolism platform using biomarkers selected from the group consisting of It can diagnose accurately.

COMPOSICAO REAGENTE E PROCESSO PARA A DETERMINACAO DE CONCENTRACOES DE GLICEROL EM FLUIDOS BIOLOGICOS

NON-HIGH DENSITY LIPOPROTEIN DERIVED CVD MARKERS

The present invention inter alia relates to methods and uses involving the determination of lipid/lipid concentration ratios in order to diagnose, predict, prevent and/or treat atherosclerosis or cardiovascular disease (CVD) and its complications including, e.g., acute myocardial infarction. The methods include analyzing lipid concentrations and resulting lipid/lipid concentration ratios of a non-high density lipoprotein samples from patients and comparing them to a control.

Low density lipoprotein triglycerides (LDL-TG) as a biomarker of cardiovascular disease and uses thereof

The invention, in some aspects, relates to methods for diagnosing cardiovascular disease, and/or detecting cardiovascular disease in a patient, and more particularly to methods of using blood-based biomarkers and their combinations to identify patients at risk of having cardiovascular disease (e.g., coronary atherosclerosis).

FREE RAPTOR REDUCES AGING- AND OBESITY-INDUCED FATTY LIVER

The present invention also provides a method of reducing a subject's hepatic and plasma triglyceride levels comprising administering to a subject in need thereof a pharmaceutical composition comprising a pharmaceutical carrier and a compound that inhibits Glucagon signaling in liver cells in an amount effective to reduce the subject's hepatic and plasma triglyceride ...

COMPOSITIONS AND METHODS FOR REDUCING A FATTY ACID DESATURATION INDEX IN A SUBJECT IN NEED THEREOF

In various embodiments, the present invention provides compositions and methods for treating and/or preventing cardiovascular-related diseases in subject in need thereof.

CHOLESTEROL EFFLUX CAPACITY ASSESSMENT

A method is provided for transforming one or more biomarkers into a cholesterol efflux capacity (CEC) value. Methods relate to determining SR-BI-mediated and ABCA1-mediated CEC. CEC may be used for compound screening and to determine risk of cardiovascular disease and to recommend or administer treatment regimens. 1. A method for determining an ABCA1-mediated cholesterol efflux capacity (CEC) of an individual comprising:obtaining a sample from an individual;measuring a triglyceride level in the sample;receiving the triglyceride level at a computing device comprising a tangible, non-transient memory coupled to a processor;transforming the triglyceride level into an ABCA1-mediated CEC value for the individual through the application, by the processor, of a predetermined rule, wherein the predetermined rule is stored in the tangible, non-transient memory; andcreating a written report comprising the ABCA1-mediated CEC value for the individual.2. The method of claim 1 , wherein the sample is a tissue sample or body fluid.3. The method of claim 2 , wherein the body fluid is blood.4. The method of claim 3 , wherein the sample is plasma from the individual.5. The method of claim 3 , wherein the sample is serum from the individual.6. The method of claim 1 , wherein application of the predetermined rule comprises multiplying a natural logarithm of the triglyceride level by a transformation coefficient.7. The method of claim 6 , wherein the rule is determined by linear regression analysis of population data wherein a plurality of values for a biomarker obtained from a plurality of individuals are compared to a plurality of corresponding measured ABCA1-mediated CEC values for the plurality of individuals to determine a transformation coefficient which best represents a correlation between the biomarker and the measured ABCA1-mediated CEC values.8. The method of claim 6 , wherein the transformation coefficient is 5.64 plus or minus 15%.9. The method of claim 1 , further ...

Means and Methods for Diagnosing Heart Failure in a Subject

The present invention relates to the field of diagnostic methods. Specifically, the present invention contemplates a method for diagnosing heart failure in a subject based on determining the amounts of at least three biomarkers. The invention also relates to tools for carrying out the aforementioned methods, such as diagnostic devices. 1. A method for diagnosing heart failure comprising the steps of: i. at least one triacylglyceride, at least one cholesterylester, and at least one phosphatidylcholine;', 'ii. at least one triacylglyceride, at least one phosphatidylcholine, and at least one sphingomyelin;', 'iii. at least one triacylglyceride, at least one cholesterylester, and at least one sphingomyelin;', 'iv. at least one phosphatidylcholine, at least one cholesterylester, and at least one sphingomyelin;', 'v. Cholesterylester C18:2, SSS and Cer(d17:1/24:0);', 'vi. at least two sphingomyelins selected from the group consisting of SM2, SM3, SM5, SM18, SM23, SM24, and SM28, and at least one triacylglyceride selected from the group consisting of SOP2, SPP1 or PPO1;', 'vii. at least two triacylglycerides selected from the group consisting of OSS2, SOP2, SPP1 and SSP2, and at least one sphingomyelin selected from the group consisting of SM23 and SM24;', 'viii. SM18, SM24 and SM28;', 'ix. the biomarkers of panel 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, ...

COMPOSITIONS AND METHODS FOR REDUCING A FATTY ACID DESATURATION INDEX IN A SUBJECT IN NEED THEREOF

In various embodiments, the present invention provides compositions and methods for treating and/or preventing cardiovascular-related diseases in subject in need thereof. 1. A method of lowering triglycerides and a fatty acid desaturation index (“FADI”) associated with a subject on statin therapy having baseline fasting triglycerides of about 200 mg/dl to about 500 mg/dl , the method comprising determining a baseline FADI level associated with the subject; and thereafter administering to the subject a pharmaceutical composition comprising about 4 grams per day of ethyl eicosapentaenoate to effect a reduction in triglycerides and the FADI associated with the subject.2. The method of further comprising determining a baseline LDL-C level associated with the subject before administering the ethyl eicosapentaenoate claim 1 , wherein the baseline LDL-C level is about 40 mg/dl to about 115 mg/dl.3. The method of claim 2 , wherein the step of administering the pharmaceutical composition effects a reduction in serum LDL-C and/or fasting triglycerides.4. The method of claim 3 , wherein the step of administering the pharmaceutical composition effects at least a 5% reduction in LDL-C and/or fasting triglycerides.5. The method of claim 3 , wherein the step of administering the pharmaceutical composition effects at least a 10% or at least a 15% reduction in triglycerides.6. The method of claim 1 , wherein the step of administering the pharmaceutical composition effects a reduction in FADI of at least about 2% claim 1 , at least about 3% claim 1 , at least about 4% claim 1 , at least about 5% claim 1 , at least about 6% claim 1 , at least about 7% claim 1 , at least about 8% claim 1 , at least about 9% claim 1 , at least about 10% claim 1 , at least about 11% claim 1 , at least about 12% claim 1 , at least about 13% claim 1 , at least about 14% claim 1 , at least about 15% claim 1 , at least about 16% claim 1 , at least about 17% claim 1 , at least about 18% claim 1 , at least ...

METHOD FOR THE HIGH-SPEED DETECTION AND/OR MEASUREMENT OF A LIPASE OR PHOSPHOLIPASE ACTIVITY

LIPID BIOMARKERS OF HEALTHY AGEING

METHOD AND REAGENT FOR QUANTIFYING CHOLESTEROL IN TRIGLYCERIDE-RICH LIPOPROTEIN

Disclosed are a method and reagent of quantifying cholesterol in triglyceride-rich lipoprotein (TRL-C) in a test sample in a more specific manner without requiring laborious operations. The method of quantifying cholesterol in triglyceride-rich lipoprotein (TRL-C) includes the steps of: (1) selectively eliminating cholesterol in lipoproteins other than triglyceride-rich lipoprotein (TRL) by allowing a cholesterol esterase having a molecular weight of more than 50 kDa and a surfactant(s) to act; and (2) quantifying the remaining TRL-C.

Method of Assessing Liver Triglyceride Levels Using a Body Fluid Sample

A method of assessing the level of triglycerides in the liver of a subject comprises determining the amount of a first lipid metabolite in a sample from the subject. The sample can be blood, plasma, serum, isolated lipoprotein fraction, saliva, urine, lymph fluid, bile, or cerebrospinal fluid. The first lipid metabolite is a fatty acid present in a lipid class. The lipid class is selected from the group consisting of free fatty acids, total fatty acids (TL), triglycerides (TG), cholesterol esters (CE), phosphatidylcholines (PC), and phosphatidylethanolamines (PE). 1. A method of assessing the level of triglycerides in the liver of a subject , comprising determining the amount of a first lipid metabolite in a blood , plasma , serum , isolated lipoprotein fraction , saliva , urine , lymph fluid , bile , or cerebrospinal fluid sample from the subject;wherein the first lipid metabolite is a fatty acid present in a lipid class; andwherein the lipid class is selected from the group consisting of free fatty acids, total fatty acids (TL), triglycerides (TG), cholesterol esters (CE), phosphatidylcholines (PC), and phosphatidylethanolamines (PE).2. The method of claim 1 , wherein the amount of the metabolite is the relative amount of the fatty acid to total fatty acid content in the lipids of one or more lipid classes in the sample.3. The method of claim 2 , wherein the relative amount is the mole percentage or the weight percentage of the lipid metabolite in the sample.4. The method of claim 1 , wherein the amount of the metabolite is the absolute amount of the lipid metabolite in the sample.5. The method of claim 4 , wherein the absolute amount of the metabolite is the concentration of the lipid metabolite in the sample.6. The method of claim 1 , wherein the first lipid metabolite is selected from the group consisting of: CE20:4n6; PC20:4n6; PE20:4n6; TL20:4n6; TG20:4n6; PC18:3n6; PC20:3n6; CE14:0; CE16:1n7; CE18:1n9; CEMUFA; CEn7; CE18:1n7; CE18:2n6; CE18:3n6; CE22:5n3; ...

Method for the High-Speed Detection and/or Measurement of a Lipase or Phospholipase Activity

The invention relates to a method for the detection and/or measurement in vitro of a lipase or phospholipase activity, characterized in that it comprises: the addition of a sample likely to contain said lipase or phospholipase into the wells of microtitration plates coated with a layer of a lipid substrate which is able to be hydrolyzed by said lipase or phospholipase by releasing alpha-eleostearic acid, the detection and/or the measurement of the lipase or phospholipase activity by UV spectrophotometry of the alpha-eleostearic acid released during the previous stage. The invention also relates to the application of the above-mentioned method to the in vitro diagnosis of pathologies linked to an increase in the plasma lipase level.

METHOD FOR DETERMINING LIVER FAT AMOUNT AND METHOD FOR DIAGNOSING NAFLD

The present invention is based on the idea of determining certain molecular lipids from a subject's blood sample, for example from serum or plasma sample, and based on the amounts of the determined lipids determining the amount of liver fat and/or diagnosing NAFLD in the subject. More specifically the subjects with elevated liver fat amount and NAFLD are characterized by elevated triglycerides with low carbon number and double bond content in the blood sample. Lysophosphatidylcholines, ether phospholipids, sphingomyelins and PUFA-containing phospholipids are diminished in the blood samples of subjects with an elevated liver fat amount and NAFLD. The method of the present invention can be further used for monitoring the subject's response to the treatment of NAFLD or to the treatment of lowering of the liver fat amount in the subject.

COMPOSITIONS AND METHODS FOR REDUCING A FATTY ACID DESATURATION INDEX IN A SUBJECT IN NEED THEREOF

In various embodiments, the present invention provides compositions and methods for treating and/or preventing cardiovascular-related diseases in subject in need thereof. 1. A method of lowering triglycerides and a fatty acid desaturation index (“FADI”) associated with a subject on statin therapy having baseline fasting triglycerides of about 200 mg/dl to about 500 mg/dl , the method comprising determining a baseline FADI level associated with the subject; and thereafter administering to the subject a pharmaceutical composition comprising about 4 grams per day of ethyl eicosapentaenoate to effect a reduction in triglycerides and the FADI associated with the subject.2. The method of further comprising determining a baseline LDL-C level associated with the subject before administering the ethyl eicosapentaenoate claim 1 , wherein the baseline LDL-C level is about 40 mg/dl to about 115 mg/dl.3. The method of claim 2 , wherein the step of administering the pharmaceutical composition effects a reduction in serum LDL-C and/or fasting triglycerides.4. The method of claim 3 , wherein the step of administering the pharmaceutical composition effects at least a 5% reduction in LDL-C and/or fasting triglycerides.5. The method of claim 3 , wherein the step of administering the pharmaceutical composition effects at least a 10% or at least a 15% reduction in triglycerides.6. The method of claim 1 , wherein the step of administering the pharmaceutical composition effects a reduction in FADI of at least about 2% claim 1 , at least about 3% claim 1 , at least about 4% claim 1 , at least about 5% claim 1 , at least about 6% claim 1 , at least about 7% claim 1 , at least about 8% claim 1 , at least about 9% claim 1 , at least about 10% claim 1 , at least about 11% claim 1 , at least about 12% claim 1 , at least about 13% claim 1 , at least about 14% claim 1 , at least about 15% claim 1 , at least about 16% claim 1 , at least about 17% claim 1 , at least about 18% claim 1 , at least ...

METHOD FOR DIAGNOSING AND TREATING COGNITIVE IMPAIRMENT AND USE THEREOF

This disclosure provides a use of biomarker SM(d18:1/24:1(15Z)) in the preparation of a reagent or kit for diagnosing cognitive impairment. This disclosure also provides a method for diagnosing and treating cognitive impairment by detecting the content of biomarkers SM(d18:1/24:1(15Z)) and TG(16:0/18:0/18:4(6Z,9Z,12Z,15Z)), PC(P-16:0/22:4(7Z,10Z,13Z,16Z) or PC(P-18:0/18:4(6Z,9Z,12Z,15Z)) to determine whether the patient has cognitive impairment.

DETERMINATION OF INTERFERENTS IN A SAMPLE

A method for determining a non-anticoagulant interferent in a blood-derived sample of a subject, the method comprising a) determining a value of a coagulation time-related parameter in the sample; b) comparing the value of the coagulation time-related parameter determined in a) to a value of the coagulation time-related parameter determined in at least one reference sample; and c) based on the result of comparison step b), determining the non-anticoagulant interferent in a blood-derived sample of a subject. A method for identifying a blood-derived sample having insufficient quality is further disclosed, the method comprising determining non-anticoagulant interferent(s) according to the aforesaid method, and to devices, kits, and uses related thereto.

Predicting the health aging lipid biological markers

在一个方面，本发明提供了一种用于预测受试者的非健康衰老风险的方法，所述方法包括：(a)测定来自所述受试者的样本中两种或更多种脂质生物标志物的水平，其中所述生物标志物选自以下组中的两个或更多个：(i)三酰基甘油(TAG)，从TAG(46:5)至TAG(54:3)；(ii)醚磷脂酰胆碱(PC‑O)，从PC‑O(28:0)至PC‑O(38:6)；(iii)鞘磷脂(SM)，从SM(33:1)至SM(50:1)；(iv)磷脂酰胆碱(PC)，从PC(32:1)至PC(40:5)；(v)磷脂酰肌醇(PI)，从PI(36:1)至PI(38:3)；(vi)磷脂酰乙醇胺(PE)，从PE(36:2)至PE(38:4)；并且(b)将所述样本中所述生物标志物的水平与参考值进行比较；其中与所述参考值相比，所述样本中所述生物标志物的水平指示所述受试者的非健康衰老风险。

Non-high density lipoprotein derived CVD markers

TREATMENT OF AUTOPHAGY-RELATED DISORDERS

The present invention relates to the use of neutral lipids, including triglycerides, diglycerides and monoglycerides which may be used to increase neutral lipids (lipid stores and/or lipid droplets) and neutral lipid stores in order to regulate (in particular, induce) autophagy and treat and/or prevent autophagy related disease states and/or conditions. In one embodiment, the invention relates to the use of neutral lipids and/or TRIM proteins which may be used to regulate (in particular, induce) autophagy, target autophagic substrates and treat and/or prevent autophagic disease states and/or conditions. 1. A method of treating or reducing the likelihood of the onset of an autophagy-mediated disease in a patient in need thereof comprising administering to said patient an effective amount of a composition comprising an effective amount of an autophagy modulator selected from the group consisting of a neutral lipid , a TRIM protein or a mixtures thereof and optionally , another bioactive agent.2. The method according to wherein said autophagy modulator is a neutral lipid.3. The method according to wherein said autophagy modulator is a TRIM protein.4. The method according to wherein said neutral lipid is effective in enhancing lipid stores and promoting lipid droplets in said patient such that enhancement of autophagy occurs.5. The method according to wherein said neutral lipid is selected from the group consisting of neutral lipids selected from the group consisting of triglycerides claim 2 , diglycerides claim 2 , monoglycerides claim 2 , glycolated mono- or diacylglycerdies claim 2 , dolichol claim 2 , polyprenol claim 2 , polyprenal or very long chain fatty acids.6. The method according to wherein said autophagy modulator is a TRIM protein selected from the group consisting of TRIM5α claim 1 , TRIM1 claim 1 , TRIM6 claim 1 , TRIM10 claim 1 , TRIM17 claim 1 , TRIM22 claim 1 , TRIM41 claim 1 , TRIM55 claim 1 , TRIM72 and TRIM76 claim 1 , among others (including TRIM 1 ...

COMPOSITIONS AND METHODS FOR THE DETECTION OF TUBERCULOSIS

Methods for diagnosis of bacterial infections (e.g., tuberculosis) are disclosed. In particular, the disclosure relates to the use of a panel of biomarkers for aiding diagnosis, prognosis, and treatment of bacterial infections such as tuberculosis. The identified biomarkers can be used to detect active infection as well as bacterial burden, and for monitoring responses to treatment.

MARKERS OF NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) AND NON-ALCOHOLIC STEATOHEPATITIS (NASH) AND METHODS OF USE THEREOF

Novel methods for assessing the level of triglycerides in the liver of a subject are described, comprising determining the amount of a lipid metabolite in a sample from a body fluid of the subject. The methods may be used, for example, in diagnosing and monitoring liver disorders such as steatosis, NAFLD and NASH.

MEANS AND METHODS FOR ASSESSING NEURONAL TOXICITY

The present invention pertains to the field of diagnostics for neuronal toxicity and toxicological assessments for risk stratification of chemical compounds. Specifically, it relates to a method for diagnosing neuronal toxicity. It also relates to a method for determining whether a compound is capable of inducing such neuronal toxicity in a subject and to a method of identifying a drug for treating neuronal toxicity. Furthermore, the present invention relates to a device and a kit for diagnosing neuronal toxicity.

DIABETES PANEL

The present invention generally relates to predicting the risk of developing diabetes in patients who currently do not have diabetes. The invention can involve obtaining a sample from a patient negative for diabetes, conducting an assay on the sample to obtain a level of a glycated albumin, and determining an elevated risk of developing a diabetic condition if the level exceeds a predetermined threshold.

METHOD FOR PREVENTING OBESITY-INDUCED FATTY LIVER BY INHIBITING KCTD17

The present invention provides methods for reducing a subject's hepatic and plasma triglyceride levels comprising administering to a subject in need thereof a pharmaceutical composition comprising a pharmaceutical carrier and a compound that decreases KCTD17 expression in liver cells in an amount effective to reduce the subject's hepatic and plasma triglyceride levels. 1. A method of reducing a subject's hepatic and plasma triglyceride levels comprising administering to a subject in need thereof a pharmaceutical composition comprising a pharmaceutical carrier and a compound that decreases KCTD17 expression in liver cells in an amount effective to reduce the subject's hepatic and plasma triglyceride levels.2. A method of reducing a subject's hepatic and plasma triglyceride levels comprising administering to a subject in need thereof a pharmaceutical composition comprising a pharmaceutical carrier and a compound that prevents PHLPP2 degradation in liver cells in an amount effective to reduce the subject's hepatic and plasma triglyceride levels.3. The method of claim 2 , wherein the pharmaceutical composition inhibits Glucagon signaling.4. A method of reducing a subject's hepatic and plasma triglyceride levels comprising administering to a subject in need thereof a pharmaceutical composition comprising a pharmaceutical carrier and a compound that inhibits Glucagon signaling in liver cells in an amount effective to reduce the subject's hepatic and plasma triglyceride levels.5. The method of claim 4 , wherein the pharmaceutical composition reduces PHLPP2 degradation.6. The method of or claim 4 , wherein the pharmaceutical composition increases free Raptor in the liver cells.7. The method of - claim 4 , wherein the pharmaceutical composition decreases PHLPP2 phosphorylation at Serine 1119 and Serine 1210 residues in liver cells.8. The method of claim 6 , wherein the pharmaceutical composition prevents PHLPP2 degradation in liver cells.9. The method of any one of - claim 6 ...

LIPID BIOMARKERS OF HEALTHY AGEING

In one aspect there is provided a method for predicting a risk of unhealthy ageing in a subject, comprising: (a) determining a level of two or more lipid biomarkers in a sample from the subject, wherein the biomarkers are selected from two or more of the following groups: (i) a triacylglycerol (TAG) from TAG (46:5) to TAG (54:3); (ii) an ether phosphatidylcholine (PC-O) from PC-O(28:0) to PC-O(38:6); (iii) a sphingomyelin (SM) from SM (33:1) to SM(50:1); (iv) a phosphatidylcholine (PC) from PC (32:1) to PC (40:5); (v) a phosphatidylinositol (PI) from PI (36:1) to PI (38:3); (vi) a phosphatidylethanolamine (PE) from PE (36:2) to PE (38:4); and (b) comparing the levels of the biomarkers in the sample to reference values; wherein the levels of the biomarkers in the sample compared to the reference values are indicative of the risk of unhealthy ageing in the subject. 1. A method for predicting a risk of unhealthy ageing in a subject , comprising: (i) a triacylglycerol (TAG) from TAG(46:1) to TAG(54:6);', '(ii) an ether phosphatidylcholine (PC-O) from PC-O(28:0) to PC-O(38:6);', '(iii) a sphingomyelin (SM) from SM(33:1) to SM(50:4);', '(iv) a phosphatidylcholine (PC) from PC(32:1) to PC(40:5);', '(v) a phosphatidylinositol (PI) from PI(36:1) to PI(38:3);', '(vi) a phosphatidylethanolamine (PE) from PE(36:2) to PE(38:4); and, '(a) determining a level of two or more lipid biomarkers in a sample from the subject, wherein the biomarkers are selected from two or more of the following groups(b) comparing the levels of the biomarkers in the sample to reference values;wherein the levels of the biomarkers in the sample compared to the reference values are indicative of the risk of unhealthy ageing in the subject.2. A method according to claim 1 , comprising determining a level of:(i) a triacylglycerol (TAG) from TAG(46:1) to TAG(54:6); and(ii) an ether phosphatidylcholine (PC-O) from PC-O(28:0) to PC-O(38:6) in the sample from the subject.3. A method according to claim 2 , ...

Method of quantifying cholesterol in triglyceride-rich lipoprotein

DETERMINATION OF INTERFERENTS IN A SAMPLE

A method for determining a non-anticoagulant interferent in a blood-derived sample of a subject, the method comprising a) determining a value of a coagulation time-related parameter in the sample; b) comparing the value of the coagulation time-related parameter determined in a) to a value of the coagulation time-related parameter determined in at least one reference sample; and c) based on the result of comparison step b), determining the non-anticoagulant interferent in a blood-derived sample of a subject. A method for identifying a blood-derived sample having insufficient quality is further disclosed, the method comprising determining non-anticoagulant interferent(s) according to the aforesaid method.

Nanoveson(TM): Treatment, Biomarkers and Diagnostic Tests for Liver Diseases and Comorbid Diseases

A method of treatment of liver diseases and comorbid diseases is disclosed wherein an oral dose of lipids in an amount effective to trigger the release of cholecystokinin (CCK) into the duodenum to generate a major release of bile phospholipids from remodeled stores of triglycerides (TAG) in the liver, is administered to a patient in need thereof, thereby causing the formation of sequestered and aggregated mixed micelles and vesicles (SAMMVs) in the intestines of the patient which are then eliminated via the bowels of the patient.

Diagnostic methods based on lipid profiles

The present invention relates to methods for the diagnosis of NAFLD in a subject, and for the differential diagnosis of NASH or steatosis in a subject suffering from NAFLD, based on the determination in a sample of metabolic markers, particularly lipid metabolic markers.

PLASMA AND LIVER LIPID SPECIES AS BIOMARKERS OF FATTY LIVER

The invention relates to plasma or liver lipid species selected from the triacylglycerol (TAG) and cardiolipin (CL) lipid classes measured by LC-MS/MS and use thereof as diagnostic and prognostic biomarkers of fatty liver, as well as to monitor the efficacy of preventive and therapeutic measures to lower liver fat content.

METHODS AND PRODUCTS FOR LABELLING LIPIDS

The present disclosure relates to methods and products for labelling, binding and/or detection of lipids. Certain embodiments provide a method of labelling a lipid. The method comprises exposing the lipid to a complex comprising a transition metal carbonyl compound, a conjugated bidentate ligand and a tetrazolato compound, and thereby labelling the lipid by binding the complex to the lipid. 151.-. (canceled)52. A method of labelling a lipid , the method comprising exposing the lipid to a complex comprising a transition metal tricarbonyl compound , a conjugated bidentate diimine ligand and a tetrazolato compound , and thereby labelling the lipid by binding the complex to the lipid.53. The method according to claim 52 , wherein the transition metal tricarbonyl compound comprises a transition metal ion comprising Re(I) and/or Ir(III).54. The method according to claim 52 , wherein the lipid comprises one or more of a polar lipid claim 52 , a non-neutral lipid claim 52 , a steroid claim 52 , a sphingomyelin claim 52 , a sphingosine claim 52 , a neutral triglyceride claim 52 , a monosialotetrahexosylganglioside claim 52 , a phosphatidylethanolamine claim 52 , a lysophosphatidic acid claim 52 , a cholesterol claim 52 , a cholesterol ester claim 52 , a steroid compound claim 52 , a steroid hormone claim 52 , a progesterone and/or a derivative of any of the aforementioned.55. The method according to claim 52 , wherein the conjugated bidentate diimine ligand comprises a phenanthroline compound and/or a bipyridine compound.56. The method according to claim 55 , wherein the phenanthroline compound comprises a 1 claim 55 ,10-phenanthroline and/or a substituted derivative thereof claim 55 , and the bipyridine compound comprises a 2 claim 55 ,2′-bipyridine and/or a substituted derivative thereof.57. The method according to claim 56 , wherein the tetrazolato compound comprises a 4-cyanophenyltetrazolate and/or a substituted derivative thereof claim 56 , a 3-pyridyltetrazolate and/ ...

Method and index for diagnosing insulin resistance

The invention provides methods for the determination of insulin sensitivity, insulin resistance, and non-insulin dependent Diabetes mellitus based on oral glucose tolerance test data and lipid ratios from reference populations that define an insulin resistance index. The invention also provides methods for using the IR index to determine disease progression and to evaluate the efficacy of therapeutic agents. The invention further provides an IR calculator for automating diagnosis, producing and storing patient medical records.

Biomarkers of Breast and Lung Cancer

Provided herein are methods of detecting lipids in humans suspected of having cancer, in particular detecting lipids in samples from a human suspected of having breast or lung cancer. 1. A method for determining amounts of lipids in a human suspected of having breast cancer , breast disease , or lung cancer comprising:providing a sample comprising a bodily fluid from the human suspected of having breast cancer, breast disease, or lung cancer;isolating exosomes from the sample;determining the amounts of lipids in a lipid set comprising at least five lipids from the isolated exosomes; andcomparing the amounts of lipids in the lipid set from the isolated exosomes to a control lipid profile using a predictive model,wherein the at least five lipids are selected from the group consisting of phosphatidyl inositol bisphosphate (PIP2), phosphatidyl inositol phosphate (PIP), Monogalactosyldiacylglycerol (MGDG), Monogalactosylmonoacylglycerol (MGMG), phosphoethanolamine (Pet), neutral glycosphingolipid (CerG2GNAc1), cyclic phosphatidyl acid (cPA), lysophosphoethanolamine (LPet), phosphosphingomyelin (phSM), and phosphomethanol (PMe), cholesterol esters (CE), triacylglyceride (TAG), lysophosphatidylcholine (Lyso-PC), lysophosphatidylcholine-plasmalogen (LysoPC-pmg), phosphatidyl choline (PC), and sphingomyelin (SM).2. The method of wherein the at least five lipids are selected from PIP2 (42:7) claim 1 , PIP2 (48:7) claim 1 , PIP2 (46:7) claim 1 , PIP2 (41:0) claim 1 , PIP (55:6) claim 1 , PIP (29:3) claim 1 , PIP (29:2) claim 1 , PIP (30:6) claim 1 , PIP (48:8) claim 1 , PIP (46:5) claim 1 , MGDG (23:6) claim 1 , MGDG (45:10) claim 1 , MGDG (46:10) claim 1 , MGDG (42:6) claim 1 , MGDG (27:7) claim 1 , MGDG (37:8) claim 1 , MGDG (26:1) claim 1 , MGDG (27:1) claim 1 , MGDG (7:0) claim 1 , MGDG (33:15) claim 1 , MGDG (13:6) claim 1 , MGMG (23:10) claim 1 , MGMG (11:3) claim 1 , Pet (28:2) claim 1 , Pet (31:2) claim 1 , Pet (22:2) claim 1 , CerG2GNAc1(34:2) claim 1 , cPA (18:2) ...

LOW DENSITY LIPOPROTEIN TRIGLYCERIDES (LDL-TG) AS A BIOMARKER OF CARDIOVASCULAR DISEASE AND USES THEREOF

The invention, in some aspects, relates to methods for diagnosing cardiovascular disease, and/or detecting cardiovascular disease in a patient, and more particularly to methods of using blood-based biomarkers and their combinations to identify patients at risk of having cardiovascular disease (e.g., coronary atherosclerosis).

DIABETES PANEL

The present invention generally relates to predicting the risk of developing diabetes in patients who currently do not have diabetes. The invention can involve obtaining a sample from a patient negative for diabetes, conducting an assay on the sample to obtain a level of a glycated albumin, and determining an elevated risk of developing a diabetic condition if said level exceeds a predetermined threshold. 1. A method for determining the risk of developing a diabetic condition , the method comprising:obtaining a sample from a patient;conducting assays on the sample to obtain levels of each of glycated albumin, glucose, adiponectin, and triglyceride;calculating body mass index (BMI) of the patient,determining a parental history of diabetes, and a statin use history;creating a diabetes risk score X using a weighted multivariate model based on the patient's BMI, the parental history of diabetes, the statin use history, and the patient's glycated albumin, glucose, adiponectin, and triglyceride, levels;2. The method of wherein the diabetes risk score is indicative of the patient developing diabetes within a period comprising at least 8 years.3. The method of further comprising comparing the diabetes risk score to a threshold level to classify the patient as high risk claim 1 , low risk or moderate risk of developing diabetes.4. The method of wherein the diabetes risk score models risk of developing diabetes with a C statistic greater than 0.85.5. The method of wherein:for every 1 mg/dl increase in the glucose level of the patient over about 95.79 mg/dl, the patient's probability of developing diabetes over a 10 year period, as indicated by the diabetes risk score, increases by about 1.17, andfor every 1 mg/dl decrease in the glucose level of the patient under about 95.79, the patient's probability of developing diabetes over a 10 year period, as indicated by the diabetes risk score, decreases by about 1.17.6. The method of wherein:for every 1 kg/m2 increase in the patient ...

DETERMINATION OF TRIGLYCERIDES AND GLYCEROL

CALIBRATION METHODS AND COMPOSITIONS FOR BIOMOLECULE ANALYSIS

Calibration standards with known amounts of combinatorial biomolecules, such as GLs, are provided. In some aspects, calibration markers of the embodiments can be used to assess or quantitate the levels of a plurality of biomolecules in a test sample, such as by mass spectrometry.

Method for determining liver fat amount and method for diagnosing nafld

The present invention is based on the idea of determining certain molecular lipids from a subject's blood sample, for example from serum or plasma sample, and based on the amounts of the determined lipids determining the amount of liver fat and/or diagnosing NAFLD in the subject. More specifically the subjects with elevated liver fat amount and NAFLD are characterized by elevated triglycerides with low carbon number and double bond content in the blood sample. Lysophosphatidylcholines, ether phospholipids, sphingomyelins and PUFA-containing phospholipids are diminished in the blood samples of subjects with an elevated liver fat amount and NAFLD. The method of the present invention can be further used for monitoring the subject's response to the treatment of NAFLD or to the treatment of lowering of the liver fat amount in the subject.

Means and methods for assessing neuronal toxicity

The present invention pertains to the field of diagnostics for neuronal toxicity and toxicological assessments for risk stratification of chemical compounds. Specifically, it relates to a method for diagnosing neuronal toxicity. It also relates to a method for determining whether a compound is capable of inducing such neuronal toxicity in a subject and to a method of identifying a drug for treating neuronal toxicity. Furthermore, the present invention relates to a device and a kit for diagnosing neuronal toxicity.

Compositions and methods for reducing a fatty acid desaturation index in a subject in need thereof

In various embodiments, the present invention provides compositions and methods for treating and/or preventing cardiovascular-related diseases in subject in need thereof.

Methods and apparatus for the analysis of fatty acids

Exemplary embodiments of the present disclosure relate to CO 2 -based chromatography for the efficient and precise separation of fatty acids. The present disclosure is based, in part, on the discovery that a CO 2 -based chromatography system with features, such as, e.g., improved pressure stability, improved sample injection, and superior column packing materials, reproducibly resolve fatty acids.

Strip for measuring blood-lipid

본 발명은 혈중 지질 측정용 스트립에 관한 것이다. 본 발명의 혈중 지질 측정용 스트립은 상부 커버 및 하부 기판 사이에 배치되는 측정 레이어의 돌출부 접촉면을 최적의 압력 또는 높이로 압착하여 생체시료의 균일 확산도를 향상시켜 생체시료 측정 결과의 정확도를 높이는 효과가 있다.

For diagnosing the lipid biomarkers of cancer

本公开提供来自胸腔积液样品的脂质生物标志物，以及其在用于确定罹患胸腔积液的患者是否患有癌症的方法中或在用于治疗罹患胸腔积液的患者中的癌症的方法中的用途。本文还公开了来自胸腔积液样品的脂质生物标志物在用于确定罹患胸腔积液的患者是否患有具有EGFR突变的癌症的方法中以及在用于治疗具有EGFR突变的患者中的癌症的方法中的用途。

Diabetes panel

The present invention generally relates to predicting the risk of developing diabetes in patients who currently do not have diabetes. The invention can involve obtaining a sample from a patient negative for diabetes, conducting an assay on the sample to obtain a level of a glycated albumin, and determining an elevated risk of developing a diabetic condition if said level exceeds a predetermined threshold. Other parameters that may be assessed is the level of glucose, adiponectin, and/or triglycerides.

Methods and apparatus for the analysis of fatty acids

Markers of non-alcoholic fatty liver disease (nafld) and non-alcoholic steatohepatitis (nash) and methods of use thereof

Markers of non-alcoholic fatty liver disease (nafld) and non-alcoholic steatohepatitis (nash) and methods of use thereof

Novel methods for assessing the level of triglycerides in the liver of a subject are described, comprising determining the amount of a lipid metabolite in a sample from a body fluid of the subject. The methods may be used, for example, in diagnosing and monitoring liver disorders such as steatosis, NAFLD and NASH.

Diabetes panel

The present invention generally relates to predicting the risk of developing diabetes in patients who currently do not have diabetes. The invention can involve obtaining a sample from a patient negative for diabetes, conducting an assay on the sample to obtain a level of a glycated albumin, and determining an elevated risk of developing a diabetic condition if said level exceeds a predetermined threshold. Other parameters that may be assessed is the level of glucose, adiponectin, and/or triglycerides.

Non-high density lipoprotein derived cvd markers

The present invention inter alia relates to methods and uses involving the determination of lipid/lipid concentration ratios in order to diagnose, predict, prevent and/or treat atherosclerosis or cardiovascular disease (CVD) and its complications including, e.g., acute myocardial infarction. The methods include analyzing lipid concentrations and resulting lipid/lipid concentration ratios of a non-high density lipoprotein samples from patients and comparing them to a control.

Glycerol 3-phosphate oxidase mutants, compositions, devices, kits and uses thereof

Compositions, devices, kits and methods are disclosed for assaying triglyceride with a glycerol 3-phosphate oxidase mutant. The glycerol 3-phosphate oxidase mutant has reduced oxidase activity while substantially maintaining, or increasing, its dehydrogenase activity, compared to the wild-type glycerol 3-phosphate oxidase.

Lipid biomarkers for the diagnosis of cancer

The present disclosure provides lipid biomarkers from pleural effusion samples and use thereof in a method for determining whether a patient suffering from pleural effusion has cancer, or in a method for treating cancer in a patient suffering from pleural effusion. Also disclosed herein is the use of lipid biomarkers from pleural effusion samples in a method for determining whether a patient suffering from pleural effusion has cancer with EGFR mutation, and in a method for treating cancer in a patient with EGFR mutation.

The quantitative approach and quantitative reagent of cholesterol in lipoprotein rich in triglycerides

公开了不需要繁杂的操作、更特异性地定量被检试样中的富含甘油三酯的脂蛋白中的胆固醇(TRL‑C)的方法以及试剂。富含甘油三酯的脂蛋白中的胆固醇的定量方法包含：通过使分子量超过50kDa的胆固醇酯酶和表面活性剂产生作用、选择性地消除富含甘油三酯的脂蛋白(TRL)以外的脂蛋白中的胆固醇的步骤(1)，和定量残存的TRL中的胆固醇(TRL‑C)的步骤(2)。

Menetelmä ärtyneen suolen oireyhtymän IBS diagnosoimiseksi

一种用于鉴定少精症的标志物、筛选方法及其应用

本发明提供了一种用于鉴定少精症的标志物、筛选方法及其应用，属于生物化学技术领域，该用于鉴定少精症的标志物，包括PE(O‑16:0/22:6)、TAG(54:8)_FA22:6、HexCer(18:1/18:1)、TAG(50:2)_FA16:0、TAG(52:7)_FA22:6、FFA(22:6)、TAG(56:8)_FA22:6、TAG(54:7)_FA22:6、TAG(56:8)_FA16:0、SM(18:1)、FFA(24:1)和DAG(16:0/18:0)，其能够解决现目前少精症的临床诊断仍存在假阳性标志物且诊断机制不明确的技术问题。

Method and reagent for quantifying cholesterol in triglyceride-rich lipoprotein

リピドミクスバックグラウンドで使用するための普遍的な脂質定量基準

本開示は、当技術分野で公知の任意の分析的な質量分析技術と共に使用することができる複数の同位体標識された脂質標準を含む普遍的な脂質定量標準（ＵＬＱＳ）を提供する。ＵＬＱＳは、以下の脂質クラスの１つ以上からの少なくとも１つの同位体的に標識された脂質種を含む：ｉ）リン脂質；ｉｉ）リゾリン脂質；ｉｉｉ）コレステロールエステル；ｉｖ）トリアシルグリセロール；ｖ）ジアシルグリセロール；ｖｉ）セラミド；及びｖｉｉ）スフィンゴミエリン。

糖尿病视网膜病变眼底硬性渗出相关的血清脂质标志物及其应用

提供了糖尿病视网膜病变眼底硬性渗出的血清脂质标志物及其应用。具体地，提供了一种糖尿病视网膜病变眼底硬性渗出相关的生物标志物集合，其中，集合包括下组的生物标志物：A1：Cer 42:0；4O、DG36:0和ADGGA 52:2。生物标志物能够高特异性、高准确度的评估人糖尿病视网膜病变眼底硬性渗出的风险或程度。

Cholesterol efflux capacity assessment

A method is provided for transforming one or more biomarkers into a cholesterol efflux capacity (CEC) value. Methods relate to determining SR-BI-mediated and ABCA1 -mediated CEC. CEC may be used for compound screening and to determine risk of cardiovascular disease and to recommend or administer treatment regimens.

Frataxin-sensitive lipid markers for monitoring frataxin replacement therapy

The present disclosure is based, at least in part, on providing a set of markers, also referred to herein as FXN-sensitive lipid markers (or FSLMs), the respective levels of which are positively or negatively correlated to frataxin (FXN) levels in a cell. Therefore, these FSLMs can be used to determine, evaluate, and/or monitor the effectiveness of FXN replacement therapy in a subject.

用于诊断和治疗认知障碍的方法及其应用

生物标志物SM(d18:1/24:1(15Z))在制备诊断认知障碍试剂或试剂盒中的应用。用于诊断和治疗认知障碍的方法，该诊断方法通过检测生物标志物SM(d18:1/24:1(15Z))以及TG(16:0/18:0/18:4(6Z,9Z,12Z,15Z))，PC(P-16:0/22:4(7Z,10Z,13Z,16Z))或PC(P-18:0/18:4(6Z,9Z,12Z,15Z))的含量，用来判断患者是否存在认知障碍。

肺高血圧症（ｐｈ）の診断のためのバイオマーカー

트리글리세리드 리치 리포단백 중의 콜레스테롤의 정량 방법 및 정량 시약

복잡한 조작을 필요로 하지 않고, 피검 시료 중의 트리글리세리드 리치 리포단백 중 콜레스테롤(TRL-C)을 보다 특이적으로 정량하는 방법 및 시약이 개시되어있다. 트리글리세리드 리치 리포단백 중 콜레스테롤의 정량 방법은 분자량이 50kDa을 초과하는 콜레스테롤 에스테라아제 및 계면활성제를 작용시킴으로써 트리글리세리드 리치 리포단백(TRL) 이외의 리포단백 중의 콜레스테롤을 선택적으로 소거하는 공정 1과, 잔존하는 TRL 중의 콜레스테롤(TRL-C)을 정량하는 공정 2를 포함한다.

富含甘油三酯的脂蛋白中的胆固醇的定量方法以及定量试剂

公开了不需要繁杂的操作、更特异性地定量被检试样中的富含甘油三酯的脂蛋白中的胆固醇(TRL‑C)的方法以及试剂。富含甘油三酯的脂蛋白中的胆固醇的定量方法包含：通过使分子量超过50kDa的胆固醇酯酶和表面活性剂产生作用、选择性地消除富含甘油三酯的脂蛋白(TRL)以外的脂蛋白中的胆固醇的步骤(1)，和定量残存的TRL中的胆固醇(TRL‑C)的步骤(2)。

体液のリピドミクス解析に基づいて癌を診断する方法

本発明は、患者の身体から採取された体液のリピドミクス解析に基づいて癌を診断する方法であって、以下の工程を含む方法を提供する。（ａ）試料に内部標準セットを加える工程であって、当該内部標準セットは上記試料に存在する脂質クラスの各々に対して１つ以上の内部標準を含んでいる工程。（ｂ）工程（ａ）の後に、上記試料を、液液リピドミクス抽出または固相リピドミクス抽出によって処理する工程。（ｃ）処理された上記試料を、質量分析法によって測定する工程。（ｄ）５１種類以上の脂質の濃度（より好ましくは、質量分析法の検出閾値を超えるレベルで存在する全ての脂質の濃度）を決定する工程であって、(i)上記脂質クラスに対応する上記内部標準を定量用に用いて、(ii)脂質の相対濃度を用いて、または、(iii)濃度比および／または信号強度を用いて、脂質の濃度を決定する工程。（ｅ）上記脂質の決定された濃度を統計評価する工程であって、上記統計評価は、決定された上記脂質濃度と、癌性パターン（あるいは任意構成で、特定の癌性パターン）および非癌性パターンとの比較に基づいて、上記患者が癌に罹患している確率のレベルを決定する（あるいは任意構成で、上記患者が特定の癌タイプに罹患している確率のレベルを決定する）工程。ここで、上記癌性パターンまたは上記特定の癌性パターンならびに非癌性パターンは、既知の癌試料群および既知の非癌試料群に対する上記脂質濃度の統計解析によって決定さる。

Método y reactivo para cuantificar el colesterol en lipoproteína rica en triglicéridos

Se divulgan un reactivo y un método que sirven para cuantificar más específicamente el colesterol (TRL-C) en lipoproteínas ricas en triglicéridos en una muestra de prueba y no requieren manipulación compleja. El método para cuantificar el colesterol en lipoproteínas ricas en triglicéridos comprende: una etapa (1) para eliminar selectivamente el colesterol en lipoproteínas distintas de las lipoproteínas ricas en triglicéridos (TRL) mediante la activación de un tensioactivo y una esterasa de colesterol que tiene un peso molecular de más de 50 kDa; y una etapa (2) para cuantificar el colesterol restante (TRL-C) en el TRL. (Traducción automática con Google Translate, sin valor legal)

Fremgangsmåde og reagensmidler til at kvantificere kolesterol i triglycerid-rigt lipoprotein

Verfahren zum nachweis und/oder zur messung einer lipase- oder phospholipaseaktivität mit hoher geschwindigkeit

폐고혈압 (ph)의 진단을 위한 바이오마커

본 발명은 환자에서 폐고혈압 (pulmonary hypertension)을 진단하는 방법, 환자에서 폐고혈압의 진행을 모니터링하는 방법, 환자에서 폐고혈압의 경중도를 결정하는 방법, 및 폐고혈압 발병 위험과 연관된 질병 및 대사 증후군으로 이루어지는 군에서 선택되는 적어도 하나의 상태와 폐고혈압을 구별하는 방법에 관한 것이다. 나아가, 본 발명은 상기 방법을 수행하기 위한 수단을 포함하는 키트에 관한 것이다.

一种用于鉴定少精症的标志物、筛选方法及其应用

本发明提供了一种用于鉴定少精症的标志物、筛选方法及其应用，属于生物化学技术领域，该用于鉴定少精症的标志物，包括PE(O‑16:0/22:6)、TAG(54:8)_FA22:6、HexCer(18:1/18:1)、TAG(50:2)_FA16:0、TAG(52:7)_FA22:6、FFA(22:6)、TAG(56:8)_FA22:6、TAG(54:7)_FA22:6、TAG(56:8)_FA16:0、SM(18:1)、FFA(24:1)和DAG(16:0/18:0)，其能够解决现目前少精症的临床诊断仍存在假阳性标志物且诊断机制不明确的技术问题。

Universal lipid quantitative standards for use in lipidomics

The present disclosure provides for a universal lipid quantitative standard (ULQS) comprising a plurality of isotopically labeled lipid standards that can be used with any analytical mass spectrometry techniques known in the art. The ULQS includes at least one isotopically labeled lipid species from one or more of the following lipid classes: i) phospholipids; ii) lysophospholipids; iii) cholesterol esters; iv) triacylglycerols; v) diacylglycerols; vi) ceramides; and vii) sphingomyelins.

Universal lipid quantitative standards for use in lipidomics

Universal lipid quantitative standards for use in lipidomics

The present disclosure provides for a universal lipid quantitative standard (ULQS) comprising a plurality of isotopically labeled lipid standards that can be used with any analytical mass spectrometry techniques known in the art. The ULQS includes at least one isotopically labeled lipid species from one or more of the following lipid classes: i) phospholipids; ii) lysophospholipids; iii) cholesterol esters; iv) triacylglycerols; v) diacylglycerols; vi) ceramides; and vii) sphingomyelins.

Universal lipid quantitative standards for use in lipidomics

The present disclosure provides for a universal lipid quantitative standard (ULQS) comprising a plurality of isotopically labeled lipid standards that can be used with any analytical mass spectrometry techniques known in the art. The ULQS includes at least one isotopically labeled lipid species from one or more of the following lipid classes: i) phospholipids; ii) lysophospholipids; iii) cholesterol esters; iv) triacylglycerols; v) diacylglycerols; vi) ceramides; and vii) sphingomyelins.

Universal lipid quantitative standards for use in lipidomics

Universal lipid quantitative standards for use in lipidomics

The present disclosure provides for a universal lipid quantitative standard (ULQS) comprising a plurality of isotopically labeled lipid standards that can be used with any analytical mass spectrometry techniques known in the art. The ULQS includes at least one isotopically labeled lipid species from one or more of the following lipid classes: i) phospholipids; ii) lysophospholipids; iii) cholesterol esters; iv) triacylglycerols; v) diacylglycerols; vi) ceramides; and vii) sphingomyelins.

用于脂质组学中的通用脂质定量标准

本公开内容提供了包含多个同位素标记的脂质标准的通用脂质定量标准(ULQS)，其可以与本领域已知的任何分析质谱法技术一起使用。ULQS包括至少一个同位素标记的脂质种类，其来自以下脂质类别中的一个或多个：i)磷脂；ii)溶血磷脂；iii)胆固醇酯；iv)三酰甘油；v)二酰甘油；vi)神经酰胺；和vii)鞘磷脂。

지질체학에서 사용하기 위한 범용 지질 정량 표준물

본 개시내용은 관련 기술분야에 공지된 임의의 분석적 질량 분석 기술과 함께 사용될 수 있는 복수의 동위원소 표지된 지질 표준물을 포함하는 범용 지질 정량 표준물 (ULQS)을 제공한다. ULQS는 하기 지질 부류 중 1종 이상으로부터의 적어도 1종의 동위원소 표지된 지질 화학종을 포함한다: i) 인지질; ii) 리소인지질; iii) 콜레스테롤 에스테르; iv) 트리아실글리세롤; v) 디아실글리세롤; vi) 세라미드; 및 vii) 스핑고미엘린.

Cholesterol efflux capacity assessment

A method is provided for transforming one or more biomarkers into a cholesterol efflux capacity (CEC) value. Methods relate to determining SR-BI-mediated and ABCA1 -mediated CEC. CEC may be used for compound screening and to determine risk of cardiovascular disease and to recommend or administer treatment regimens.

Cholesterol efflux capacity assessment

Biomarkers

in one aspect., the present Invention provides a method of determining cardiovascular disease (CVD) risk in a subject comprising (a) determining fatty acid composition of lipids In a sample obtained from the subject, wherein the lipids are selected from the group consisting of: (I) triacylgiycerols (TAGs); and cholesterol esters (CEs); and (b) comparing the fatty acid composition of the lipids in the sample from the subject to a control; wherein a decrease in mean fatty acid chain length in the lipids in the sample from the subject compared to the control indicates an. increased risk of CVD in the subject; and wherein the. CVD is associated with atherosclerotic plaque rupture or thrombosis., and/or the CVD Is an acute ischemic event selected from myocardial infarction, ischemic stroke or sudden cardiac death.

Frataxin-sensitive lipid markers for monitoring frataxin replacement therapy

The present disclosure is based, at least in part, on providing a set of markers, also referred to herein as FXN-sensitive lipid markers (or FSLMs), the respective levels of which are positively or negatively correlated to frataxin (FXN) levels in a cell. Therefore, these FSLMs can be used to determine, evaluate, and/or monitor the effectiveness of FXN replacement therapy in a subject.

Method for the High-Speed Detection and/or Measurement of a Lipase or Phospholipase Activity

The invention relates to a method for the detection and/or measurement in vitro of a lipase or phospholipase activity, characterized in that it comprises: the addition of a sample likely to contain said lipase or phospholipase into the wells of microtitration plates coated with a layer of a lipid substrate which is able to be hydrolyzed by said lipase or phospholipase by releasing α-eleostearic acid, the detection and/or the measurement of the lipase or phospholipase activity by UV spectrophotometry of the α-eleostearic acid released during the previous stage. The invention also relates to the application of the above-mentioned method to the in vitro diagnosis of pathologies linked to an increase in the plasma lipase level.

Procedimiento de detección y/o de medición a alto caudal de una actividad lipásica o fosfolipásica.

Procedimiento de preparación de placas de microtitulación que comprenden unos pocillos revestidos con un sustrato lipídico, que puede ser hidrolizado por una lipasa o una fosfolipasa liberando ácido α-eleosteárico, caracterizado porque comprende las etapas siguientes: - añadir a los pocillos de dichas placas una composición que comprende el sustrato lipídico en disolución en un disolvente apropiado susceptible de poder ser evaporado al vacío, siendo esta adición, llegado el caso, efectuada después del lavado de los pocillos de dichas placas con dicho disolvente, - evaporar al vacío dicho disolvente hasta la formación de un revestimiento con dicho sustrato lipídico de 0,5 a 5 µm, y preferentemente de 1 µm de grosor en las paredes de los pocillos de las placas de microtitulación.

一种差异脂质分子作为脂质标志物的用途及试剂盒

本发明为一种差异脂质分子作为脂质标志物的用途及试剂盒，涉及生物医学技术领域，所述差异脂质分子包括甘油三酯、磷脂酰乙醇胺，并且本发明提供的包含所述差异脂质分子的试剂盒为差异脂质分子作为发育性髋关节发育不良的脂质标志物的用途及其研究提供更多的选择和支持，且易操作，能快速批量检测，检测准确率高，具有广阔的产业推广价值。

一种区分吸食电子烟和烟草烟的装置和方法

本发明提供一种区分吸食电子香烟和纸烟的装置以及方法，该装置包括：用于检测样本中尼古丁或者其类似物的测试条；用于检测样本中甘油的测试条。利用本发明的装置和方法有效区分吸食者吸食的是电子烟还是烟草产品，利于提供治疗尼古丁滥用这更加准确的治疗和干预方案。

Methods for measuring and montoring a meat characteristic of a livestock animal from a sample obtained from a non-meat location of the livestock

The invention is directed to a method of livestock breeding, meat production and marketing, histology, and genetics using a biopsy sample from a non-meat location of the livestock to provide information about the meat quality of the livestock.

Preservative for in vitro diagnostic reagent and use thereof

The embodiments of the present application, belonging to the technical field of medical test and assay, and provide a preservative for an in vitro diagnostic reagent. The preservative includes a combination of a sulfadoxine solution and a dimethoprim solution, wherein a molar ratio of sulfadoxine in the sulfadoxine solution to dimethoprim in the dimethoprim solution is from 0.002 to 1. The present disclosure also provides use of the preservative for the in vitro diagnostic reagent. The technical solutions according to the embodiments of the present disclosure improve stability of the reagent, do not affect reactions of the reagent, and may be extensively applied.

用于糖尿病合并冠心病诊断的代谢标志物和应用

本申请涉及一种用于糖尿病合并冠心病诊断的代谢标志物和应用，代谢标志物包括水溶性代谢标志物和脂溶性代谢标志物。本申请的代谢标志物可用于实现对糖尿病患者中糖尿病合并冠心病的特异性诊断，且完全不适用于非糖尿病人群中的冠心病患者和非冠心病人群的区分和诊断。

一种提取组织或细胞中甘油三酯的方法

本发明公开了一种提取组织或细胞中甘油三酯的方法，涉及生物分析领域。包括以下步骤：(1)用甘油标准液做标准曲线，获得标准曲线方程式；(2)将组织与KOH溶液混合，研磨匀浆，孵育后离心取上清；(3)取上清于96微孔板中，加入甘油三酯测定试剂，反应后采用酶标仪测定读数，结后标准曲线方程式计算含量。本申请用KOH匀浆测定肝脏甘油三酯含量的方法与传统的用氯仿/甲醇提取法相比,既避免了有毒溶剂的使用保障使用者的健康，又能快速准确的测定肝脏中甘油三酯含量，实验步骤简单，实验周期较短，为小鼠肝脏组织的甘油三酯含量的测定提供了一个新的方法。

一种差异脂质分子作为脂质标志物的用途及试剂盒

本发明为一种差异脂质分子作为脂质标志物的用途及试剂盒，涉及生物医学技术领域，所述差异脂质分子包括甘油三酯、磷脂酰乙醇胺，并且本发明提供的包含所述差异脂质分子的试剂盒为差异脂质分子作为发育性髋关节发育不良的脂质标志物的用途及其研究提供更多的选择和支持，且易操作，能快速批量检测，检测准确率高，具有广阔的产业推广价值。